Albinism B-BCVA improves in early school years

Article

Albinos experience an improvement in binocular best-corrected visual acuity (B-BCVA).

Albinos experience an improvement in binocular best-corrected visual acuity (B-BCVA), according to an investigation in the Journal of Paediatric Ophthalmology and Strabismus.

The study, headed by Dr Johanna M. Dijkstal, Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, USA, involved the investigation of B-BCVA in albino patients. The information recorded included type of albinism, B-BCVA, glasses wear, iris pigment, macular transparency grade and presence or absence of an annular reflex and melanin in the macular. Each patient was visited between the ages of 5.5 and 9 years (Visit A) and 9.5 and 14 years (Visit B) with a gap of at least 2.5 years between visits.

Visit A revealed a mean B-BCVA of 20/84 and Visit B demonstrated a mean B-BCVA of 20/61, meaning B-BCVA improved by 80%. There was no strong correlation between improvement in B-BCVA and glasses wear, iris grade, macular grade, macular melanin, and annular reflex.

However, from Visit A and Visit the team discovered a moderate correlation between B-BCVA and iris grade. The study showed that B-BCVA frequently improves in albinism in the early school years. It is said to be linked to changes in nystagmus, use of precise null point, developmental maturation, and ocular characteristics.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.